Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Healthy Volunteers
Interventions: Vortioxetine, Paroxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Encino, California • Long Beach, California • Torrance, California + 12 more

Conditions: Preterm Birth
Interventions: Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio

Conditions: Anxiety
Interventions: Psilocybin (drug), Niacin, MRI; Drug · Other · Diagnostic Test
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Torrance, California

Conditions: Chronic Kidney Disease
Interventions: Kibow Biotics; Dietary Supplement
Lead sponsor: Kibow Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Healthy Adults
Interventions: Naltrexone and 2-butanol, 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form); Drug
Lead sponsor: Xhale Assurance; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Duloxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 56
States / cities: Beverly Hills, California • Chino, California • Garden Grove, California + 53 more

Conditions: Blood Sugar, Endothelial Function
Interventions: PEAK ATP® with GlycoCarn®, PEAK ATP®, GlycoCarn®, Placebo; Dietary Supplement · Other
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Celiac Disease
Interventions: Larazotide Acetate, placebo; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 56
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 52 more

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: Gastroparesis
Interventions: VLY-686 (Tradipitant), Placebo; Drug · Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 38
States / cities: Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 34 more

Conditions: Obesity
Interventions: methylsulfonylmethane, placebo; Dietary Supplement
Lead sponsor: Lindsey Miller; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Obscure Gastrointestinal Bleeding (Occult or Overt)
Interventions: Capsule endoscopy, Dedicated small bowel contrast radiography; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 24 more

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Ritalin LA (methylphenidate hydrochloride extended release); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more

Conditions: Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions: Gentamicin, Lactobacillus Rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: NBI-1117568, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Garden Grove, California • La Habra, California • Lemon Grove, California + 17 more

Conditions: Depression
Interventions: Citalopram, Methylphenidate (MPH), Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myasthenia Gravis
Interventions: Placebo, 250 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Fresno, California • Orange, California • San Francisco, California + 12 more

Conditions: Muscular Dystrophy, Duchenne
Interventions: Edasalonexent, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more

Conditions: Nonalcoholic Fatty Liver
Interventions: PXL770, Placebo; Drug
Lead sponsor: Poxel SA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Autistic Disorder
Interventions: D-cycloserine, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Anxiety, Stress
Interventions: KMS-66 Ashwagandha 300mg, placebo capsule; Dietary Supplement
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain, Postoperative
Interventions: Bupivacaine HCl 0.5% Injectable Solution, Dexamethasone, Infiltration between Popliteal Artery and Capsule of the knee (iPACK), Percocet 5Mg-325Mg Tablet; Drug · Procedure
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions: Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo; Combination Product · Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 45
States / cities: Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more

Search by objective public record fields.

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Assessment of DHA On Reducing Early Preterm Birth

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis

An Adherence Tool to Manage Narcotic -Addicted HIV Patients

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health

Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

Safety and Effectiveness of D-Cycloserine in Children With Autism

Prospective, Multi Centric, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KSM-66 Ashwagandha (Withania Somnifera) in Adults Experiencing High Stress and/or Anxiety

Post Operative Pain Management for ACL Reconstruction

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies